

Original Research

View Article online



Received 10 January 2026

Revised 27 January 2026

Accepted 29 January 2026

Available Online 17 April 2026

Edited by Balamuralikrishnan Balasubramanian

## KEYWORDS:

Oral squamous cell carcinoma

Network pharmacology

Molecular docking

Molecular dynamics simulation

Phytochemicals

*Syzygium cumini*

Natr Resour Human Health 2026; 6 (2): 474–493

<https://doi.org/10.53365/nrhh/217527>

eISSN: 2583-1194

Copyright © 2026 Visagaa Publishing House

## Integrative network pharmacology, molecular docking, and molecular dynamics simulations reveal potential anticancer mechanisms of *syzygium cumini* phytochemicals against oral squamous cell carcinoma

Srividhya Srinivasan<sup>1</sup>, Palani Bharath<sup>2</sup>, Saraswathi Gopal K.<sup>1</sup>, B. Anand<sup>3</sup>, Thirumal Kumar D.<sup>2\*</sup>

<sup>1</sup>Department of Oral Medicine and Radiology, Meenakshi Ammal Dental College and Hospital, Meenakshi Academy of Higher Education and Research, India.

<sup>2</sup>Research, Central Research Laboratory, Meenakshi Academy of Higher Education and Research, India.

<sup>3</sup>Department of Oral Medicine and Radiology, Ragas Dental College & Hospital, India.


**ABSTRACT:** Oral squamous cell carcinoma (OSCC) is one of the most prevalent forms of oral malignancies, and its treatment procedures include surgery, radiation therapy, and chemotherapy. However, patients experience various adverse effects, and sometimes the treatment becomes ineffective due to resistance, leading to recurrence. *Syzygium cumini*, a plant with high medicinal value, such as antioxidant, anticancer, and antimicrobial properties, was used in this study against OSCC. The study aims to investigate the potential pharmacological mechanisms of *S. cumini* in the treatment of OSCC using a network pharmacology approach, molecular docking, and MD simulations. The active phytochemicals of *S. cumini* were collected using the IMPPAT database and filtered using SwissADME. Further, their respective targets were collected using SwissTargetPrediction. OSCC targets were retrieved from the GeneCards database, and their common targets were identified using a Venn diagram. The PPI network was built using STRING and Cytoscape. Subsequently, the core targets were obtained using MCODE, while the gene-disease-associated targets were obtained via DisGeNET. Molecular docking and simulations were performed for the protein-ligand complexes. The potential targets identified from the PPI networks include MAPK1, PTGS2, ESR1, MMP9, and PARP1. Molecular docking revealed that the MMP9-Geranyl butyrate, PTGS2-Ledol, and ESR1-(-)-Globulol complexes exhibited the highest binding affinities. MD simulation confirmed that these compounds exhibited strong, stable interactions, as well as compactness, with their corresponding targets. We identified the key compounds Geranyl butyrate, Ledol, and (-)-Globulol from *S. cumini* that effectively bind to OSCC targets and might play a vital role in the treatment.

\* Corresponding author.

E-mail address: [thirumalkumard@gmail.com](mailto:thirumalkumard@gmail.com) (Thirumal Kumar D.)

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## GRAPHICAL ABSTRACT



## 1. INTRODUCTION

Oral squamous cell carcinoma accounts for approximately 90% of all oral malignancies and is one of the most prevalent forms of oral cancer in South Asia (Chai et al., 2020). High incidence and mortality rates have been observed in Asia compared to other regions, and it mostly affects middle-aged and elderly men (Bugshan & Farooq, 2020). OSCC arises from squamous epithelial cells due to uncontrolled growth and affects the mouth, lips, tongue, and other regions of the oral cavity (Miguelanez-Medran et al., 2019). The oral cavity and oropharynx are the common sites affected in OSCC (Bugshan & Farooq, 2020). The significant risk factors for OSCC are linked to various habits, such as tobacco smoking, alcohol intake, betel nut chewing, human papillomavirus infection, nutritional deficiency, immune deficiency, and other lifestyle habits (Choi et al., 2025; Zhao et al., 2024). These factors contribute to OSCC through chronic inflammation in cells, DNA damage, and genetic modifications (M. Li et al., 2025). Smoking aids in tumor progression by suppressing immunity in the oral region and increases the risk of carcinogenesis by affecting tumor suppressor genes, such as p53 and PTEN (Tan et al., 2023). Cigarettes contain various harmful substances, including nitrosamines, aromatic amines, and polycyclic aromatic hydrocarbons (PAHs), which increase the risk of OSCC (Imbesi Bellantoni et al., 2023). Another common cause is alcohol consumption, and the synergistic effects of alcohol use and smoking further increase the risk (Feller et al., 2013). Likewise, betel nut chewing, along with tobacco, is more carcinogenic (approximately 15 times) than without smoking. It releases reactive oxygen species (ROS), which cause toxicity, genetic alterations, and initiate tumorigenesis (P.-H. Chen et al., 2017). Compounds such as arecoline

and arecaidine from betel nut can trigger DNA damage and induce OSCC (Y.-C. Li et al., 2019). Apart from these causes, genetic alterations and epigenetic modifications also contribute to OSCC development (Tan et al., 2023). At present, treatment methods such as chemotherapy, radiotherapy, and surgical procedures are used to treat oral cancers (Kijowska et al., 2024). Despite several treatment methods, patient outcomes in OSCC are compromised due to the development of resistance to chemotherapeutic agents, including cisplatin and 5-fluorouracil. Moreover, patients experience severe side effects during treatment procedures and may experience recurrence. Notably, this type of cancer is often diagnosed at later stages, where treatment becomes more difficult, leading to poor survival rates (Gormley, 2022; Menditti et al., 2023).


Plant-based medicines have been used for many centuries in various traditional medicine systems as an alternative to synthetic drugs. These plant-based products offer several advantages to the human body, making them a more affordable option for multiple treatments, including cancer (Ramsridhar et al., 2025). Natural compounds from various plants have shown promising therapeutic potential for use in cancer therapy due to their antitumor properties. They contain multiple kinds of active phytochemicals, such as alkaloids, terpenoids, flavonoids, and phenolic compounds (Lichota & Gwozdziński, 2018). These compounds exhibit no or low toxicity, are readily available, and are low cost, which makes them potential candidates in cancer treatment (Yu et al., 2022). Additionally, these compounds can inhibit cell growth and induce apoptosis by targeting various cancer-related pathways involved in tumor development and metastasis (Choudhari et al., 2020).

*Syzygium cumini* is a member of the Myrtaceae family, commonly known as Jamun, Indian blackberry, Java plum,

or Malabar plum. It is widely found in tropical and subtropical regions, with its origin in India and Indonesia (Das et al., 2023). Various parts of *S. cumini*, including fruits, seeds, bark, and leaves, possess significant medicinal value and have been used for centuries in various traditional medicine systems such as Siddha, Ayurveda, Unani, Homeopathy, and Chinese medicine to treat various diseases (L. Li et al., 2021). These components contain various active phytochemicals, including flavonoids, anthocyanins, phenols, and terpenoids, which exert antioxidant, anti-inflammatory, antimicrobial, anti-diabetic, antiviral, and anticancer properties (Chhikara et al., 2018; Sawant et al., 2015). The fruits are purple to blackish in color due to high anthocyanin content (Gajera et al., 2018). In addition to anthocyanins, the fruits contain condensed and hydrolysable tannins (such as ellagitannins and gallotannins), predominantly found in the skin, which are a natural source of antioxidants that exhibit strong antioxidant capabilities (Das et al., 2023; Tavares et al., 2016). The fruit has been used to treat various physiological illnesses such as dysentery, gastric issues, and other digestive problems. These are rich in fiber, vitamins, and minerals such as calcium, potassium, and iron (Qamar et al., 2022). Additionally, jamun fruits are a good source of carbohydrates such as glucose, fructose, sucrose, and maltose, as well as amino acids such as alanine, asparagine, and tyrosine (Al-Dhabi & Ponmurugan, 2020; Aqil et al., 2012). Consuming this fruit offers several health benefits, and it has been used for the management of diabetes since ancient

times in traditional medicine (Qamar et al., 2022). It lowers blood sugar levels in diabetic patients and also helps in purifying the blood. Due to the presence of iron, it boosts hemoglobin levels and acts as a blood-purifying agent (El-Safy et al., 2023). *S. cumini*, being a rich reservoir of various bioactive phytoconstituents, has gained significant interest in the field of pharmacology and ethnomedicine (Ravi Ahirwar\*, 2025).

Recently, the network pharmacology approach has been extensively utilized in drug discovery to unveil the therapeutic mechanisms of herbal- and traditional-based medicines in the treatment of various diseases (S. Yang et al., 2024). This approach has shifted the paradigm from the traditional single-target, single-drug process to a multi-target, multi-drug concept in which drugs act on multiple targets (Zhai et al., 2021). Network pharmacology integrates bioinformatics and systems biology to analyze complex compound-target interactions involved in disease treatment (Sakuludomkan et al., 2025). This work aims to identify the active phytochemical compounds of *Syzygium cumini* and elucidate their mechanism of action for the treatment of OSCC. A network pharmacology-based approach was employed, integrating molecular docking and MD simulation analysis to explore the therapeutic potential of *S. cumini*. This approach helped identify key phytochemical compounds, potential molecular targets, and underlying pathways involved in the pathogenesis of OSCC. The graphical abstract is shown in Figure 1.



**Figure 1.** Graphical representation of the study workflow integrating network pharmacology, molecular docking, and molecular dynamics simulations (MDS) to investigate the therapeutic potential of *Syzygium cumini* phytochemicals against OSCC.

## 2. MATERIALS AND METHODS

### 2.1. Conceptual Design, Study Hypothesis, and Data retrieval

This work is an *in silico* study conducted between June 2025 and October 2025, utilizing publicly available datasets, bioinformatics analyses, and molecular modelling workflows. The study was designed as a hypothesis-driven *in silico* investigation to elucidate the potential molecular mechanisms by which phytochemicals derived from *Syzygium cumini* may exert therapeutic effects against OSCC, using an integrative approach. This study did not involve human participants, patient data, or animals and did not require ethics committee approval or informed consent. The bioactive compounds present in *Syzygium cumini* were obtained using the IMPPAT database (Mohanraj et al., 2018). The botanical name of the Jamun fruit, “*Syzygium cumini*”, was used as the keyword to search for the phytochemicals. The phytochemical compounds present in the fruit were collected and considered for this study.

### 2.2. Screening of Bioactive Compounds and Target Identification

The obtained active compounds were subjected to ADME analysis using SwissADME to predict their drug-likeness and oral bioavailability, which are crucial in determining the characteristics of drugs (Daina et al., 2017). Compounds that did not satisfy these criteria were excluded from further studies. The potential targets of the selected compounds of *Syzygium cumini* were predicted using SwissTargetPrediction (Daina et al., 2019). The SMILES of each phytochemical was used as the query to retrieve targets relevant to *Homo sapiens* with a probability score of 1 and were taken for subsequent analysis.

### 2.3. Prediction of OSCC-related target genes

Collecting disease-related genes is essential for understanding the mechanisms of herbal formulations or plant-derived products and their active phytochemicals in disease therapy. The genes associated with OSCC were collected from the GeneCards database using the keyword “oral squamous cell carcinoma” (Stelzer et al., 2016)

### 2.4. Construction of a Venn diagram

The potential common targets associated with OSCC and the active phytochemicals in jamun fruit were identified using the GeneVenn tool. This tool generated a Venn diagram

comprising potential overlapping targets of OSCC and the jamun fruit. The UniProt ID of the protein targets was given as input in the Venn diagram tool.

### 2.5. Gene Ontology (GO) and Pathway Mapping of Common Targets

The potential overlapping targets were subjected to GO and KEGG enrichment analyses using the Metascape tool (Zhou et al., 2019). The UniProt ID of the protein targets was given as the input, and the species was selected as *Homo sapiens*. Metascape is a curated tool that analyses gene sets by integrating various ontology sources such as GO Biological Processes, KEGG pathways, and Reactome Gene Sets. The p-values and q-values in the Metascape tool were calculated based on the cumulative hypergeometric distribution and Benjamini–Hochberg, which help in multiple testing, thereby improving the reliability of enrichment results. Terms with p-value of < 0.01, q-value of < 0.05, and an enrichment factor > 1.5 were considered statistically significant.

### 2.6. PPI Network Analysis and Hub Target Extraction

The UniProt ID of protein targets was submitted to the STRING database to build a protein–protein interaction (PPI) network with a threshold of 0.4 (medium confidence) (Szklarczyk et al., 2023). The output file was downloaded from STRING and imported into Cytoscape software for better visualization and further analysis (Shannon et al., 2003). The MCODE plugin was used to identify the highly connected PPI sub-network or clustered targets within the network by adjusting specific parameters—node score cutoff (0.2), K-Core cutoff (2), maximum depth (100), and degree cutoff (2). DisGeNET, another plugin, was used to identify gene–disease associations related to OSCC.

### 2.7. Molecular Docking

Molecular docking was performed for the identified protein targets with their corresponding phytoconstituents using AutoDock Tools v1.5.6 (Morris et al., 2009). The proteins were prepared by adding necessary charges and converted into PDBQT format. Similarly, all ligands were converted into the same format, and docking was carried out. The binding sites were defined for every target protein, and the grid box was generated accordingly. The default parameters of the Lamarckian Genetic Algorithm were utilized to perform docking, and the binding affinities between each

protein and ligand were calculated. BIOVIA Discovery Studio v24.1.0.23298 was employed to visualize the interactions within the protein–ligand complexes (Dassault Systèmes BIOVIA, n.d.).

## 2.8. MD simulations

Based on molecular docking, the top three protein–ligand complexes with the highest binding affinities were selected for simulation using the GROMACS 2023.2 package (Abraham et al., 2023). The protein parameterization was performed using the CHARMM27 force field, while the ligand topology was generated through the SwissParam webserver (Zoete et al., 2011). The complexes were converted into GROMACS format, and the hydrogen atoms were removed. The TIP3P water model was utilized to solvate the complexes. Subsequently, neutralization of the system was achieved by adding appropriate counter ions. Following this, an energy minimization step was performed using the steepest descent integrator to eliminate steric clashes and hindrances within the complexes. All systems were subjected to equilibration, which was carried out in two steps, namely, the NVT and the NPT ensembles. During NVT and NPT equilibration, the Berendsen thermostat (Berendsen et al., 1984) was used to maintain constant volume for 100 ps and a constant temperature of 310 K, while the Parrinello–Rahman barostat (Parrinello & Rahman, 1981) was used to maintain a pressure of 1 bar for 100 ps, respectively. A production run of 100 ns was performed after the equilibration phases, and the output trajectory files were analyzed to compute root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), hydrogen bond (H-bond), and solvent accessible surface area (SASA).

## 3. RESULTS

### 3.1. Prediction of Bioactive Compounds

Using the IMPPAT database, we obtained a total of 32 active compounds that were present in the *Syzygium cumini* (fruit) and are shown in Table S1.

### 3.2. Screening of Bioactive Compounds and Target Identification

Using SwissADME, the pharmacokinetic properties (Absorption, Distribution, Metabolism, and Excretion) of the compounds were predicted, and the compounds that satisfied

Lipinski's rule of five were screened (zero and one violation) (Table S2). A total of 29 compounds were retrieved, as only three compounds violated the rule of five and were excluded. The potential human targets for the screened compounds were obtained using SwissTargetPrediction. We obtained 731 human targets with a probability value of 1 for the 29 screened compounds related to OSCC (Supplementary File 1).

### 3.3. Prediction of OSCC-related target genes


A total of 9,873 target genes related to OSCC were retrieved from the GeneCards database, out of which 8620 are protein-coding genes and were selected and considered for further analysis (Supplementary File 2).

### 3.4. Construction of a Venn diagram

The common targets that overlap between OSCC-related targets and the targets of *S. cumini* were identified using a Venn diagram. The intersection of these targets resulted in 29 overlapping targets and was considered a key target that might play a major role in OSCC (Figure S1).

### 3.5. Gene Ontology (GO) and Pathway Mapping of Common Targets


A total of 290 overlapping targets were subjected to Gene Ontology (GO) and pathway enrichment analyses using the Metascape tool. More than 50 genes were associated with biological processes (BP), including cellular response to hormone stimulus (GO:0032870), regulation of hormone levels (GO:0010817), regulation of secretion by cell (GO:1903530), cellular response to nitrogen compound (GO:1901699), and regulation of MAPK cascade (GO:0043408), which emerged as the most significantly enriched terms. Additionally, other processes such as regulation of trans-synaptic signaling (GO:0099177), regulation of inflammatory response (GO:0050727), response to alcohol (GO:0097305), and protein phosphorylation (GO:0006468) were also significantly enriched for BP. KEGG pathway enrichment analysis revealed that neuroactive ligand–receptor interaction and neuroactive ligand signaling were the most significantly enriched pathways, with 18.3% and 12.8% of the genes involved, respectively. Additionally, the Nuclear Receptor transcription pathway, Phase I – Functionalization of compounds, and Reversible hydration of carbon dioxide were identified from Reactome pathway enrichment, which correspond to 4.14% and 8.62% of genes (Figure 2).



**Figure 2.** Gene Ontology (GO) and KEGG enrichment analyses of common targets identified using Metascape.

### 3.6. PPI Network Analysis and Hub Target Extraction


The protein–protein interaction (PPI) network was built using STRING (Figure S2), and the output file was downloaded in tsv format, which is compatible with Cytoscape. The PPI network contains 94 nodes and 2687 edges, with an average node degree of 18.7 and an average local clustering coefficient of 0.45. Subsequent analyses were performed using Cytoscape software. Using the MCODE plugin, we identified a total of 19 core targets, namely Mitogen-activated protein kinase 14 (MAPK14), hepatocyte growth factor receptor (MET), Vascular endothelial growth factor receptor 2 (KDR), glycogen synthase kinase-3 beta (GSK3B), Peroxisome proliferator-activated receptor gamma (PPARG), Estrogen receptor beta (ESR2), protein tyrosine kinase 2 (PTK2), insulin-like growth factor I receptor (IGF1R), Mitogen-activated protein kinase 1 (MAPK1), Cyclin-dependent kinase 2 (CDK2), Androgen receptor (AR), Mitogen-activated protein kinase 8 (MAPK8), Progesterone receptor (PGR), matrix metalloproteinase 2 (MMP2), poly [ADP-ribose] polymerase-1 (PARP1), matrix metalloproteinase 9 (MMP9), Prostaglandin G/H synthase 2 (PTGS2), Heme oxygenase 1 (HMOX1), and Estrogen receptor (ESR1) (Figure 3). To determine the relevance to OSCC, we performed gene–disease association analysis using DisGeNET and identified several targets within the obtained core target hub. These include MAPK1, PTGS2, ESR1, MMP2, MMP9, and PARP1 (Figure 4). These targets were associated with OSCC, indicating their potential involvement in disease pathogenesis and were considered for molecular docking.



**Figure 3.** Identification of the top 19 hub genes from the protein–protein interaction network using the MCODE plugin in Cytoscape.

### 3.7. Molecular Docking

Based on the PPI network and hub target analysis using STRING, Cytoscape, and DisGeNET, six OSCC-related targets were selected: MAPK1, PTGS2, ESR1, MMP2, MMP9, and PARP1, and molecular docking was performed for these targets with their corresponding phytochemicals. Among all active phytochemicals, Geranyl butyrate exhibited the highest binding energy of -9.04 kcal/mol with MMP9. Similarly, Ledol exhibited the second-highest binding energy of -8.98 kcal/mol with PTGS2. Following this, (-)-Globulol



**Figure 4.** Identification of six OSCC-related target genes through gene-disease association analysis using DisGeNET.

exhibited the third-highest binding energy of  $-8.55$  kcal/mol with ESR1. The binding energies of all the phytochemicals and protein targets are shown in Table 1, and the interactions of the top three protein–ligand complexes are shown in Figure 5.

### 3.8. MD simulations

MD simulations were performed to further evaluate the impact of *S. cumini* active phytochemicals on OSCC-related targets. The top three protein–ligand complexes, MMP9–Geranyl butyrate, PTGS2–Ledol, and ESR1–(-)-Globulol, which had the highest binding energies, were selected for simulation.

The MMP9–Geranyl butyrate complex exhibited a stable RMSD value with no significant fluctuations throughout the simulation. The complex attained equilibrium after 50 ns, suggesting higher stability due to the binding of Geranyl butyrate. Meanwhile, the MMP9–Apo protein displayed high deviations up to  $\sim 0.34$  nm but reached equilibrium after 80 ns (Figure 6A). RMSF analysis revealed that the MMP9 complex exhibited low flexibility across most residues; however, in certain regions between  $\sim 180$ – $200$  and  $209$ – $218$ , deviations up to  $\sim 0.25$  and  $0.3$  nm were observed, respectively. In the Apo protein, higher fluctuations were observed compared to the complex, with the highest peak reaching up to  $\sim 0.47$  nm at residues  $\sim 170$ – $187$  (Figure 6B). From the Rg plot, both the ligand-bound and unbound MMP9 exhibited Rg values within the range of  $\sim 1.48$ – $1.55$  nm. The Apo protein maintained its compactness up to  $\sim 55$  ns, after


**Table 1**

Binding energies of OSCC targets with their corresponding *Syzygium cumini* phytochemicals.


Target proteins	Phytochemical compounds	PubChem ID	Binding affinity
MMP9	Geranyl butyrate	5355856	$-9.04$ kcal/mol
MMP2	Geranyl butyrate	5355856	$-7.54$ kcal/mol
MAPK1	Palmitic acid	985	$-5.84$ kcal/mol
ESR1	(-)-Globulol	12304985	$-8.55$ kcal/mol
	Widdrol	94334	$-8.67$ kcal/mol
	Oleanolic acid	10494	$-7.83$ kcal/mol
	Linalool	6549	$-5.68$ kcal/mol
	alpha-Pinene	6654	$-5.83$ kcal/mol
	beta-Pinene	14896	$-5.83$ kcal/mol
	beta-Caryophyllene	5281515	$-7.99$ kcal/mol
	6-Epi-beta-bisabolol	12300148	$-6.69$ kcal/mol
	Ledol	11074994	$-8.53$ kcal/mol
PTGS2	Ledol	11074994	$-8.98$ kcal/mol
	cis-Nerolidol	5320128	$-6.02$ kcal/mol
	Linalool	6549	$-5.9$ kcal/mol
PARP1	gamma-Decalactone	12813	$-5.91$ kcal/mol
	cis-Dihydrocarvone	443181	$-6.4$ kcal/mol

which an increase in the peak up to  $\sim 1.57$  nm was observed. However, the Apo protein converged at the end of the simulation, indicating that it attained a conformational state with high compactness similar to the bound state. On the other hand, the complex did not show any major deviations from the beginning to the end of the simulation, indicating better compactness (Figure 6C). The SASA analysis revealed that the MMP9–Apo structure exhibited more fluctuations compared to the complex, with fluctuations up to  $\sim 100$  nm<sup>2</sup> observed throughout the simulation. The MMP9 complex exhibited lower SASA values compared to the Apo form and converged, indicating a reduced solvent-accessible surface area (Figure 6D).

The RMSD plot for PTGS2 showed that the Apo form exhibited higher RMSD values than the PTGS2–Ledol complex. During the initial phase of the simulation, the PTGS2–Apo structure displayed a significant increase in its peaks; however, after  $\sim 25$  ns, the system reached an equilibrium state and maintained an RMSD value between  $\sim 0.2$ – $0.3$  nm. Meanwhile, the complex structure attained its equilibrium state after 30 ns and maintained a stable state up to  $\sim 80$  ns. Towards the end, a slight increase in the trend was observed, reaching up to  $\sim 0.25$  nm, but still lower than the Apo form (Figure 7A). Both systems displayed variable fluctuations and distinct peaks at various regions, which might correspond to loops or unstructured areas. The complex structure indicates a



**Figure 5.** Two-dimensional interaction profiles of the top three protein-ligand complexes. (A) MMP9 with Geranyl butyrate, (B) PTGS2 with Ledol, (C) ESR1 with (-)-Globulol.




**Figure 6.** MDS analysis of the MMP9-Geranyl butyrate complex, depicting (A) root mean square deviation (RMSD), (B) root mean square fluctuation (RMSF), (C) radius of gyration (Rg), and (D) solvent-accessible surface area (SASA) profiles, highlighting the structural stability, flexibility, compactness, and solvent exposure of the complex throughout the simulation period.

**Color scheme:** MMP9-Apo is shown in blue, and the MMP9-Geranyl butyrate complex is shown in violet.

stable conformation with overall lower flexibility in several key regions. In the case of the Apo form, significant peaks were observed at residues 75 (~ 0.35 nm) and 145 (~ 0.31 nm), respectively, indicating that these regions were highly flexible (Figure 7B). In Rg analysis, higher Rg values were observed for the Apo protein, with minimal deviations after ~ 35 ns.

The complex structure exhibited relatively lower Rg values than the Apo protein and reached equilibrium around 50 ns, suggesting that the protein maintained its structural compactness throughout the simulation (Figure 7C). Higher SASA values were observed for the PTGS2-Apo system, up to ~ 265 nm<sup>2</sup>, whereas lower SASA values were observed for the



**Figure 7.** MDS analysis of the PTGS2-Ledol complex, depicting (A) root mean square deviation (RMSD), (B) root mean square fluctuation (RMSF), (C) radius of gyration (Rg), and (D) solvent-accessible surface area (SASA) profiles, highlighting the structural stability, flexibility, compactness, and solvent exposure of the complex throughout the simulation period.

**Color scheme:** PTGS2-Apo is shown in magenta, and the PTGS2-Ledol complex is shown in cyan.


complex, indicating that the protein was tightly packed with fewer solvent-exposed areas (Figure 7D).

The RMSD plot for ESR1 revealed that the Apo protein exhibited constant fluctuations ranging from  $\sim 0.2$ – $0.3$  nm throughout the simulation period. In contrast, the ESR1–(-)-Globulol complex exhibited relatively lower RMSD values than the Apo form, indicating a more stable conformation. After the initial rise, the complex maintained its stability, and convergence was observed at the end (Figure 8A). From the RMSF analysis, a higher fluctuation pattern was observed for the ESR1-Apo protein, with the highest deviations up to  $\sim 0.5$  nm and  $0.36$  nm at residues 551 and 535, respectively. Meanwhile, the complex demonstrated lower fluctuation patterns across most residues, except at positions 307 ( $\sim 0.5$  nm), 465 ( $\sim 0.33$  nm), and 578 ( $\sim 0.32$  nm), where higher flexibility was observed compared to the Apo form (Figure 8B). The Rg analysis revealed that the complex was more tightly packed, with no significant structural changes observed, confirming its compactness and rigidity. In contrast, the Apo form showed slightly higher Rg values than the complex; however, both systems converged at the end of the simulation (Figure 8C). In the ESR1–(-)-Globulol complex, fluctuations were observed in the initial phase up to  $\sim 20$  ns, after which the system maintained consistently lower SASA values until

$\sim 70$  ns. A sudden peak was observed, indicating slight conformational changes in the protein, after which it converged at the end. In the case of the Apo protein, higher fluctuations were observed, implying that the protein adopted a more open conformation, making it more accessible to the solvent (Figure 8D).

#### 4. DISCUSSION

Oral squamous cell carcinoma is one of the most prevalent cancer types in the head and neck region and is responsible for 90% of the morbidity and mortality (Chamoli et al., 2021). Mainly, smoking, alcohol consumption, and betel nut chewing contribute to OSCC development, and these habits are predominantly observed in countries such as India, Taiwan, and other Southeast Asian countries (Hao et al., 2024). Patients often suffer from various adverse reactions during treatment, which remains a challenge in OSCC (Alqarni et al., 2024). Moreover, the 5-year survival rate of OSCC patients remains lower than 50% due to metastasis and disease recurrence even after treatment, highlighting the need for alternative therapeutic strategies (Cristaldi et al., 2019). Plant-based medicines are now widely used as an



**Figure 8.** MDS analysis of the ESR1(-)-Globulol complex, depicting (A) root mean square deviation (RMSD), (B) root mean square fluctuation (RMSF), (C) radius of gyration (Rg), and (D) solvent-accessible surface area (SASA) profiles, highlighting the structural stability, flexibility, compactness, and solvent exposure of the complex throughout the simulation period.

**Color scheme:** ESR1-Apo is shown in turquoise, and the ESR1(-)-Globulol complex is shown in maroon.

alternative or as an adjuvant in cancer therapy due to their minimal or no adverse effects compared to chemotherapeutic drugs (Hashim et al., 2024). This study aimed to investigate the potential pharmacological mechanisms of *Syzygium cumini* in the treatment of OSCC by employing a network pharmacology approach along with molecular docking and simulation analysis.

The compounds of *S. cumini* were retrieved and filtered based on Lipinski's rule of five using the SwissADME tool. Subsequently, human targets for these compounds were identified. On the other hand, OSCC-related genes were collected, and the common overlapping targets associated with OSCC and the targets of *S. cumini* compounds were identified using a Venn diagram. This significant overlap suggests that multiple targets are commonly involved in both, thus indicating a potential therapeutic relevance of *S. cumini* in OSCC. Further GO and KEGG functional enrichment analyses revealed various significant biological processes and molecular pathways involved in the pathogenesis of OSCC (Figure 2). The most significant biological processes involved in OSCC include cellular response to hormone stimulus, regulation of hormone levels, regulation of the MAPK cascade, regulation of inflammatory response, and response to alcohol. While OSCC is not hormone dependent, the observed results, such

as cellular response to hormone stimulus and regulation of hormone levels, suggest a potential role in OSCC. The MAPK signaling pathways are cascades of three kinases, including MAP kinase kinase kinase (MAPKKK), MAP kinase kinase (MAPKK), and MAP kinase (MAPK). This pathway is primarily involved in cell growth, cell migration, apoptosis, angiogenesis, and metastasis. Deregulation or aberrant activation of this pathway leads to tumorigenesis (Lee et al., 2020; Peng et al., 2017). In any type of cancer, inflammation plays a significant role, including OSCC. Chronic inflammation may lead to the production of cytokines, growth factors, and ROS, which can cause DNA damage, leading to cancer (Singh et al., 2022). Notably, the response to alcohol shows a strong epidemiological association between chronic alcohol consumption and OSCC incidence, as alcohol is linked to approximately 26% of all oral malignancies globally (Tenore et al., 2020).

A PPI network was constructed for the overlapping targets using the STRING database. The STRING network was imported into Cytoscape, and subsequently, the MCODE plugin was utilized to identify the key targets such as MAPK14, ESR2, PTK2, MAPK1, AR, MAPK8, PARP1, MMP9, PTGS2, and ESR1 (Figure 3). Furthermore, DisGeNET was used to perform gene-disease association analysis, and six targets, namely MAPK1, PTGS2, ESR1,

MMP2, MMP9, and PARP1, were identified (Figure 4). MAPK1, also known as ERK2, is a member of the mitogen-activated protein kinase (MAPK) signaling pathway, which plays a critical role in regulating various cellular functions, including cell survival, proliferation, apoptosis, and cellular metabolism (Z. Li et al., 2020). Phosphorylation of MAPK1 leads to the activation of downstream signaling pathways and promotes cell migration and proliferation, making it a critical regulatory factor in the progression of OSCC (S. Huang et al., 2024). Overexpression of PTGS2 facilitates angiogenesis and promotes tumor progression by modulating and stabilizing the tumor microenvironment (TME) (Frejborg et al., 2020). It also causes inflammation, prevents apoptosis, and contributes to treatment resistance (Kamal et al., 2024). Tobacco chewing leads to increased expression of PTGS2 and has been detected in oral tissues of affected individuals (R.-Y. Huang & Chen, 2011). There are only a few studies reported for ESR1 in the context of OSCC. In one study, expression of ESR1 was observed, but it was rare in OSCC cases; however, the overall survival rates were decreased in male patients (Doll et al., 2021). Several studies reported the overexpression of MMP2 and MMP9 in OSCCs (Baker et al., 2006; De Vicente et al., 2005; Mashhadiabbas et al., 2012; Mohtasham et al., 2013; Pramanik & Mishra, 2022; Tamamura et al., 2013; Ye et al., 2008). MMP2 and MMP9 are classes of metalloproteinases that play a crucial role in the degradation of the extracellular matrix (ECM) and are associated with tumor invasion and metastasis, including OSCC (Lu et al., 2014; Sanyal et al., 2022). In OSCC, the basement membrane functions as the first barrier of the ECM, separating epithelial and mesenchymal cells, which must be degraded for tumor invasion and metastasis. Both MMP2 and MMP9, in their activated forms, degrade the ECM and type IV collagen, thereby facilitating invasion and metastasis (Kato et al., 2005). Some studies reported that MMP2 is also linked with ERK and/or p38 activity (Chang et al., 2021; W.-E. Yang et al., 2019). The expression of MMP2 has been shown to increase with advanced tumor stage, high histological grade, and tumor invasiveness. It has also been linked with the ERK1/2 signaling pathway, highlighting its importance in OSCC progression (Shrestha et al., 2017). Meanwhile, MMP9 has been associated with the aggressive nature of OSCC (Vilen et al., 2013). In tongue cancer, a subtype of OSCC, elevated MMP9 expression is strongly associated with increased proliferation of tumor cells. The overexpression of MMP9 promotes the degradation of ECM components, predominantly type IV collagen, leading to basement membrane thinning. This process facilitates tumor cell invasion, metastasis, and angiogenesis (Fan et al., 2012). High levels of MMP9 have been found in advanced stages of OSCC and correlate with tumor progression and invasion (Patil et al., 2021). MMP9

can be used as a biomarker to measure metastatic potential in OSCC, and its levels vary according to tumor grade (Patel et al., 2005). In one study, the expression of PARP1 was found to be significantly elevated in patient-derived OSCC tissue samples (Kossatz et al., 2016). In another study, OSCC tumor cells derived from recurrent cases showed significantly higher expression of PARP1. These elevated levels of PARP1 contribute to resistance and recurrence in OSCC (Wang et al., 2022).

The corresponding bioactive compounds of the targets obtained from DisGeNET majorly fall under terpenoids. Terpenoids are natural bioactive compounds with numerous pharmacological benefits, which are made up of isoprene units (Guo et al., 2024). These compounds exhibit various biological properties such as antioxidant, anti-inflammatory, anticancer, and antimicrobial properties (Mitea et al., 2025).

Some terpenoids can inhibit cell differentiation and activate apoptosis, leading to suppression of tumorigenesis. Additionally, these compounds can inhibit angiogenesis and metastasis at advanced stages of cancer (Kamran et al., 2022). Geranyl butyrate, a monoterpene, was synthesized from geraniol to determine anticancer activity *in vitro*, and the study revealed that it demonstrated potent cytotoxic activity against murine leukemia (P388) cells (Widiyarti et al., 2019). A study by Rodríguez et al. demonstrated that Globulol (a sesquiterpene) exhibits antioxidant properties and may be utilized as a potential therapeutic agent to neutralize free radicals (Rodríguez et al., 2019). El-Shiekh et al. reported that Globulol had antioxidant and antifungal properties (El-Shiekh et al., 2024). Oleanolic acid exhibits pharmacological properties including antidiabetic, anti-inflammatory, antioxidant, immune-boosting, hepatoprotective, anticancer, and antiviral effects (Günther & Bednarczyk-Cwynar, 2025; Wasim & Bergonzi, 2024). It possesses significant antioxidant properties that can be used to prevent many diseases related to oxidative stress (Günther & Bednarczyk-Cwynar, 2025). Widdrol has shown potent anticancer effects in human colon adenocarcinoma cells *in vitro* by inhibiting cell growth and inducing apoptosis (Kwon et al., 2010). Similarly, another *in vitro* study demonstrated its anti-cancer activity in colon cancer cells by inducing cell death (Kim, 2012).  $\alpha$ -Pinene, one of the isomers of Pinene, is a vital monoterpene with anticancer activities against human ovarian cancer cell lines and hepatocellular carcinoma cell lines. It can induce apoptosis, disrupt ROS formation, and display several inhibitory effects on hepatocellular carcinoma cell lines, including BEL-7402 cells and HepG2 cells under *in vitro* conditions (W. Chen et al., 2015; J.-B. Yang et al., 2016). It also exerts anti-inflammatory and antioxidant properties. Meanwhile, the other isomer,  $\beta$ -Pinene, is also observed to have inhibitory effects on leukemia, breast cancer, and non-small cell lung cancer (combined with paclitaxel) (Salehi et al., 2019).

Linalool has been shown to possess potent anticancer activity in an ovarian cancer model and in hepatocellular carcinoma cell lines (Kłos & Chlubek, 2022). It also showed anticancer potential in leukemia and melanoma (Ansari & Akhtar, 2019). Other sesquiterpenoid compounds, such as  $\beta$ -caryophyllene and cis-Nerolidol, possess various biological effects, including anti-inflammatory, antioxidant, and antimicrobial properties (Chan et al., 2016; Gushiken et al., 2022), while 6 Epi beta bisabolol has anti-inflammatory activity (Egbuta et al., 2022). As these compounds mainly possess antioxidant and chemopreventive properties, they may effectively neutralize ROS and induce cell death. Due to their lipophilic and hydrophobic nature, these compounds are capable of interacting with the lipid bilayer and can target multiple intracellular signaling pathways. Additionally, they can modulate the MAPK signaling pathway, which plays a critical role in the activation and progression of the oral carcinogenetic cascade (Kumar & Jha, 2023; Sharmila et al., 2025). Through these complementary mechanisms, the compounds may serve as supportive agents in the management of OSCC.

Molecular docking of the OSCC targets with their respective phytochemicals revealed strong binding interactions. The highest binding energies were observed for the MMP9–Geranyl butyrate, PTGS2–Ledol, and ESR1–(-)-Globulol complexes. Geranyl butyrate and Ledol were also found to interact with MMP2 and ESR1. Similarly, ESR1 was targeted by multiple compounds, including Widdrol, Oleanolic acid, Linalool, alpha-Pinene, beta-Pinene, beta-Caryophyllene, and 6-epi-beta-bisabolol. All these compounds exhibited strong binding interactions with the OSCC targets (Table 1). Metalloproteinases (MMP2 and MMP9), which play a major role in degrading ECM to facilitate tumor metastasis in OSCC, were effectively targeted by the compounds of *S. cumini*. MD simulations were performed for the top three protein–ligand complexes to assess their binding stability. The MMP9–Geranyl butyrate complex exhibited stable and low RMSD values, indicating greater stability. RMSF analysis revealed less flexibility across major residues, while Rg confirmed the compactness of the complex. SASA analysis also confirmed that the ligand-bound complex had a more stable conformation with less solvent exposure (Figure 6). The PTGS2–Ledol complex exhibited lower RMSD values, indicating a more stable form than the Apo structure. RMSF analysis showed that the complex had less flexibility compared to its Apo form. Additionally, Rg and SASA analyses revealed that the complex attained a more compact and stable conformation, as evidenced by its lower Rg and SASA values (Figure 7). In the ESR1–Globulol complex, RMSD, RMSF, Rg, and SASA analyses revealed that both the complex and

the Apo form exhibited similar fluctuations throughout the simulation period (Figure 8).

The compounds Geranyl butyrate, Ledol, and (-)-Globulol contributed to the stabilization of their respective protein targets. The bioactive compounds of *S. cumini* interacted with multiple targets that are clinically associated with tumorigenesis in OSCC, indicating their potential translational relevance. The network pharmacology approach enabled the identification of multi-target effects, which is a key advantage of computational approaches. Nevertheless, this study has certain limitations. It is solely based on *in silico* approaches and is therefore considered hypothesis-generating. Important parameters such as release profile index (RPI), long-term toxicity, enhanced permeability and retention (EPR) effects, and pharmacokinetic behavior, which are critical for translational assessment, were not evaluated in this study and will be investigated in future research (Bommanavar et al., 2025). Further experimental studies using oral cancer cell lines and *in vivo* models are needed to validate these findings and assess their biological and clinical relevance. Overall, this network pharmacology-based approach improves our understanding of the mechanisms of *S. cumini* compounds and highlights their potential therapeutic role in OSCC.

## CONCLUSION

In this study, a network pharmacology approach was employed to explore the pharmacological and molecular mechanisms of *Syzygium cumini* for treating OSCC. Through a Venn diagram, 290 common targets associated with OSCC and *S. cumini* were identified. Several important biological processes, such as hormone regulation, inflammatory response, and MAPK signaling, were identified through enrichment analysis, which play a critical role in OSCC. The core targets identified from the network have significant relevance and importance in the context of OSCC. The six targets (MAPK1, PTGS2, ESR1, MMP2, MMP9, and PARP1) identified from the gene–disease association analysis were considered the top targets, and their corresponding bioactive compounds were docked against them. Geranyl butyrate, Ledol, and (-)-Globulol were identified as the key bioactive compounds that exhibited strong binding affinity with the targets. Furthermore, MD simulations confirmed the stable binding interactions of these compounds with the OSCC targets, suggesting their potential roles as therapeutic agents for OSCC. However, further validation is required to support these computational findings.

**ETHICAL APPROVAL**

Not applicable as the study involved computational simulations.

**FINANCIAL SUPPORT AND SPONSORSHIP**

Nil

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**AUTHOR CONTRIBUTIONS**

S.S.: Research concept and design, Collection and/or assembly of data, Data analysis and interpretation, Writing the article; P.B.: Collection and/or assembly of data, Data analysis and interpretation, Writing the article; S.G.K.: Critical revision of the article, Final approval of the article; B.A.: Writing the article, Critical revision of the article, Final approval of the article; T.K.D.: Research concept and design, Critical revision of the article, Final approval of the article.

**ORCID**

Srividhya Srinivasan	0000-0002-3491-8253
Palani Bharath	0009-0004-0880-0851
Saraswathi Gopal K	0000-0002-4279-2494
B Anand	0009-0001-9036-8372
Thirumal Kumar D	0000-0002-5545-606X

**REFERENCES**

- Abraham, M., Alekseenko, A., Bergh, C., Blau, C., Briand, E., Doijade, M., Fleischmann, S., Gapsys, V., Gaurav Garg, Gorelov, S., Gouaillardet, G., Gray, A., M. Eric Irrgang, Jalalypour, F., Jordan, J., Junghans, C., Prashanth Kanduri, Keller, S., Kutzner, C., ... Lindahl, E. (2023). *GROMACS 2023.2 Manual*. <https://doi.org/10.5281/ZENODO.8134388>
- Al-Dhabi, N. A., & Ponnuragan, K. (2020). Microwave assisted extraction and characterization of polysaccharide from waste jamun fruit seeds. *International Journal of Biological Macromolecules*, 152, 1157–1163. <https://doi.org/10.1016/j.ijbiomac.2019.10.204>
- Alqarni, A., Hosmani, J., Alassiri, S., Alqahtani, A. M. A., & Assiri, H. A. (2024). A Network Pharmacology Identified Metastasis Target for Oral Squamous Cell Carcinoma Originating from Breast Cancer with a Potential Inhibitor from F. sargassaceae. *Pharmaceuticals*, 17(10), 1309. <https://doi.org/10.3390/ph17101309>
- Ansari, I. A., & Akhtar, M. S. (2019). Current Insights on the Role of Terpenoids as Anticancer Agents: A Perspective on Cancer Prevention and Treatment. In M. K. Swamy & M. S. Akhtar (Eds.), *Natural Bio-active Compounds* (pp. 53–80). Springer Singapore. [https://doi.org/10.1007/978-981-13-7205-6\\_3](https://doi.org/10.1007/978-981-13-7205-6_3)
- Aqil, F., Gupta, A., Munagala, R., Jeyabalan, J., Kausar, H., Sharma, R. J., Singh, I. P., & Gupta, R. C. (2012). Antioxidant and Antiproliferative Activities of Anthocyanin/Elagitanin-Enriched Extracts From *Syzygium cumini* L. (*Jamun*, the Indian Blackberry). *Nutrition and Cancer*, 64(3), 428–438. <https://doi.org/10.1080/01635581.2012.657766>
- Baker, E. A., Leaper, D. J., Hayter, J. P., & Dickenson, A. J. (2006). The matrix metalloproteinase system in oral squamous cell carcinoma. *British Journal of Oral and Maxillofacial Surgery*, 44(6), 482–486. <https://doi.org/10.1016/j.bjoms.2005.10.005>
- Berendsen, H. J. C., Postma, J. P. M., Van Gunsteren, W. F., DiNola, A., & Haak, J. R. (1984). Molecular dynamics with coupling to an external bath. *The Journal of Chemical Physics*, 81(8), 3684–3690. <https://doi.org/10.1063/1.448118>
- Bommanavar, S., Prabhu, V., Sidheeque, A., Shenoy, S., Saiduth, K., & Kumar, A. (2025). A Concept Centric Synthesis Matrix Framework (SMF) on Application of Green Biomarkers in OSCC. *Oral and Maxillofacial Pathology Journal*, 16(2), 267–275.
- Bugshan, A., & Farooq, I. (2020). Oral squamous cell carcinoma: Metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. *F1000Research*, 9, 229. <https://doi.org/10.12688/f1000research.22941.1>
- Chai, A. W. Y., Lim, K. P., & Cheong, S. C. (2020). Translational genomics and recent advances in oral squamous cell carcinoma. *Seminars in Cancer Biology*, 61, 71–83. <https://doi.org/10.1016/j.semcancer.2019.09.011>
- Chamoli, A., Gosavi, A. S., Shirwadkar, U. P., Wangdale, K. V., Behera, S. K., Kurrey, N. K., Kalia, K., & Mandoli, A. (2021). Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics. *Oral Oncology*, 121, 105451. <https://doi.org/10.1016/j.oraloncology.2021.105451>
- Chan, W.-K., Tan, L., Chan, K.-G., Lee, L.-H., & Goh, B.-H. (2016). Nerolidol: A Sesquiterpene Alcohol with Multi-Faceted Pharmacological and Biological Activities. *Molecules*, 21(5), 529. <https://doi.org/10.3390/molecules21050529>
- Chang, W., Tsai, C., Yang, J., Hsu, Y., Shih, L., Chiu, H., Bau, D., & Tsai, F. (2021). Resveratrol inhibited the metastatic behaviors of cisplatin-resistant human oral cancer cells via phosphorylation of ERK/p-38 and suppression of MMP-2/9. *Journal of Food Biochemistry*, 45(6). <https://doi.org/10.1111/jfbc.13666>
- Chen, P.-H., Mahmood, Q., Mariottini, G. L., Chiang, T.-A., & Lee, K.-W. (2017). Adverse Health Effects of Betel Quid and the Risk of Oral and Pharyngeal Cancers. *BioMed Research International*, 2017, 1–25. <https://doi.org/10.1155/2017/3904098>
- Chen, W., Liu, Y., Li, M., Mao, J., Zhang, L., Huang, R., Jin, X., & Ye, L. (2015). Anti-tumor effect of  $\alpha$ -pinene on human hepatoma cell lines through inducing G2/M cell cycle arrest. *Journal of Pharmacological Sciences*, 127(3), 332–338. <https://doi.org/10.1016/j.jphs.2015.01.008>
- Chhikara, N., Kaur, R., Jaglan, S., Sharma, P., Gat, Y., & Panghal, A. (2018). Bioactive compounds and pharmacological and food applications of *Syzygium cumini*—a review. *Food & Function*, 9(12), 6096–6115. <https://doi.org/10.1039/c8fo00654g>

- Choi, Y. J., Saravanakumar, K., Joo, J.-H., Nam, B., Park, Y., Lee, S., Park, S., Li, Z., Yao, L., Kim, Y., Irfan, N., & Cho, N. (2025). Metabolomics and network pharmacology approach to identify potential bioactive compounds from *Trichoderma* sp. Against oral squamous cell carcinoma. *Computational Biology and Chemistry*, 115, 108348. <https://doi.org/10.1016/j.combiolchem.2025.108348>
- Choudhari, A. S., Mandave, P. C., Deshpande, M., Ranjekar, P., & Prakash, O. (2020). Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice. *Frontiers in Pharmacology*, 10. <https://doi.org/10.3389/fphar.2019.01614>
- Cristaldi, M., Mauceri, R., Di Fede, O., Giuliana, G., Campisi, G., & Panzarella, V. (2019). Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives. *Frontiers in Physiology*, 10, 1476. <https://doi.org/10.3389/fphys.2019.01476>
- Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Scientific Reports*, 7(1), 42717. <https://doi.org/10.1038/srep42717>
- Daina, A., Michielin, O., & Zoete, V. (2019). SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. *Nucleic Acids Research*, 47(W1), W357–W364. <https://doi.org/10.1093/nar/gkz382>
- Das, G., Nath, R., Das Talukdar, A., Ağagündüz, D., Yilmaz, B., Capasso, R., Shin, H.-S., & Patra, J. K. (2023). Major Bioactive Compounds from Java Plum Seeds: An Investigation of Its Extraction Procedures and Clinical Effects. *Plants*, 12(6), 1214. <https://doi.org/10.3390/plants12061214>
- Dassault Systèmes BIOVIA. (n.d.). *Discovery Studio* (Version 24.1.0.23298) [Computer software]. <https://discover.3ds.com/discovery-studio-visualizer-download>
- De Vicente, J. C., Florentino Fresno, M., Villalain, L., Antonio Vega, J., & Hernández Vallejo, G. (2005). Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. *Oral Oncology*, 41(3), 283–293. <https://doi.org/10.1016/j.oraloncology.2004.08.013>
- Doll, C., Bestendonk, C., Kreuzer, K., Neumann, K., Pohrt, A., Trzpis, I., Koerdt, S., Dommerich, S., Heiland, M., Raguse, J.-D., & Jöhrens, K. (2021). Prognostic Significance of Estrogen Receptor Alpha in Oral Squamous Cell Carcinoma. *Cancers*, 13(22), 5763. <https://doi.org/10.3390/cancers13225763>
- Egbuta, M. A., McIntosh, S., Waters, D. L. E., Vancov, T., & Liu, L. (2022). In Vitro Anti-Inflammatory Activity of Essential Oil and  $\beta$ -Bisabolol Derived from Cotton Gin Trash. *Molecules*, 27(2), 526. <https://doi.org/10.3390/molecules27020526>
- El-Safy, S., Khalifa, A. M., Almashad, A. A., Mohamed Khalil, A. M., Hammad, E. M., Sami, R., Aljahani, A. H., Pareek, S., Helal, M., Alharthi, S., & Taha, I. M. (2023). Utilization of Jamun Fruit (*Syzygium cumini* L.) for Value Added Food Products. *Journal of Food Quality*, 2023, 1–10. <https://doi.org/10.1155/2023/5460642>
- El-Shiekh, R. A., Okba, M. M., Mandour, A. A., Kutkat, O., Elshimy, R., Nagaty, H. A., & Ashour, R. M. (2024). Eucalyptus Oils Phytochemical Composition in Correlation with Their Newly Explored Anti-SARS-CoV-2 Potential: In Vitro and in Silico Approaches. *Plant Foods for Human Nutrition*, 79(2), 410–416. <https://doi.org/10.1007/s11130-024-01159-w>
- Fan, H.-X., Li, H.-X., Chen, D., Gao, Z.-X., & Zheng, J.-H. (2012). Changes in the expression of MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell carcinoma: Relationships and prognostic implications. *Journal of Experimental & Clinical Cancer Research*, 31(1), 90. <https://doi.org/10.1186/1756-9966-31-90>
- Feller, L., Chandran, R., Khammissa, R. a. G., Meyerov, R., & Lemmer, J. (2013). Alcohol and oral squamous cell carcinoma. *SADJ: Journal of the South African Dental Association = Tydskrif van Die Suid-Afrikaanse Tandheelkundige Vereniging*, 68(4), 176–180.
- Frejborg, E., Salo, T., & Salem, A. (2020). Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis. *International Journal of Molecular Sciences*, 21(23), 9246. <https://doi.org/10.3390/ijms21239246>
- Gajera, H. P., Gevariya, S. N., Patel, S. V., & Golakiya, B. A. (2018). Nutritional profile and molecular fingerprints of indigenous black jamun (*Syzygium cumini* L.) landraces. *Journal of Food Science and Technology*, 55(2), 730–739. <https://doi.org/10.1007/s13197-017-2984-y>
- Gormley, M. (2022). An update on oral cavity cancer: Epidemiological trends, prevention strategies and novel approaches in diagnosis and prognosis. *Community Dental Health*, 39(3), 197. [https://doi.org/10.1922/CDH\\_00032Gormley09](https://doi.org/10.1922/CDH_00032Gormley09)
- Günther, A., & Bednarczyk-Cwynar, B. (2025). Oleanolic Acid: A Promising Antioxidant—Sources, Mechanisms of Action, Therapeutic Potential, and Enhancement of Bioactivity. *Antioxidants*, 14(5), 598. <https://doi.org/10.3390/antiox14050598>
- Guo, J., Huang, M., Hou, S., Yuan, J., Chang, X., Gao, S., Zhang, Z., Wu, Z., & Li, J. (2024). Therapeutic Potential of Terpenoids in Cancer Treatment: Targeting Mitochondrial Pathways. *Cancer Reports*, 7(9), e70006. <https://doi.org/10.1002/cnr2.70006>
- Gushiken, L. F. S., Beserra, F. P., Hussni, M. F., Gonzaga, M. T., Ribeiro, V. P., De Souza, P. F., Campos, J. C. L., Massaro, T. N. C., Hussni, C. A., Takahira, R. K., Marcato, P. D., Bastos, J. K., & Pellizzon, C. H. (2022). Beta-caryophyllene as an antioxidant, anti-inflammatory and re-epithelialization activities in a rat skin wound excision model. *Oxidative Medicine and Cellular Longevity*, 2022(1), 9004014. <https://doi.org/10.1155/2022/9004014>
- Hao, P., Zhang, P., Liu, Y., Cao, Y., Du, L., Gao, L., & Dong, Q. (2024). Network pharmacology and experiment validation investigate the potential mechanism of triptolide in oral squamous cell carcinoma. *Frontiers in Pharmacology*, 14, 1302059. <https://doi.org/10.3389/fphar.2023.1302059>
- Hashim, G. M., Shahgolzari, M., Hefferon, K., Yavari, A., & Venkataraman, S. (2024). Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals. *Bioengineering*, 12(1), 7. <https://doi.org/10.3390/bioengineering12010007>
- Huang, R.-Y., & Chen, G. G. (2011). Cigarette smoking, cyclooxygenase-2 pathway and cancer. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, 1815(2), 158–169. <https://doi.org/10.1016/j.bbcan.2010.11.005>
- Huang, S., Zhang, J., Qiao, Y., Pathak, J. L., Zou, R., Piao, Z., Xie, S., Liang, J., & Ouyang, K. (2024). CHRDL1 inhibits OSCC metastasis via MAPK signaling-mediated inhibition of MED29. *Molecular Medicine*, 30(1), 187. <https://doi.org/10.1186/s10020-024-00956-y>
- Imbesi Bellantoni, M., Picciolo, G., Pirrotta, I., Irrera, N., Vaccaro, M., Vaccaro, F., Squadrito, F., & Pallio, G. (2023). Oral Cavity Squamous Cell Carcinoma: An Update of the

- Pharmacological Treatment. *Biomedicines*, 11(4), 1112. <https://doi.org/10.3390/biomedicines11041112>
- Kamal, M. V., Damerla, R. R., Parida, P., Rao, M., Belle, V. S., Dikhit, P. S., Palod, A., Gireesh, R., & Kumar, N. A. (2024). Expression of *PTGS2* along with genes regulating *VEGF* signalling pathway and association with high-risk factors in locally advanced oral squamous cell carcinoma. *Cancer Medicine*, 13(3), e6986. <https://doi.org/10.1002/cam4.6986>
- Kamran, S., Sinniah, A., Abdulghani, M. A. M., & Alshawsh, M. A. (2022). Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review. *Cancers*, 14(5), 1100. <https://doi.org/10.3390/cancers14051100>
- Kato, K., Hara, A., Kuno, T., Kitaori, N., Huilan, Z., Mori, H., Toida, M., & Shibata, T. (2005). Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: Manifestation and localization of their activity. *Journal of Cancer Research and Clinical Oncology*, 131(6), 340–346. <https://doi.org/10.1007/s00432-004-0654-8>
- Kijowska, J., Grzegorzczak, J., Gliwa, K., Jędras, A., & Sitarz, M. (2024). Epidemiology, Diagnostics, and Therapy of Oral Cancer—Update Review. *Cancers*, 16(18), 3156. <https://doi.org/10.3390/cancers16183156>
- Kim, H. (2012). Widdrol induces apoptosis via activation of AMP-activated protein kinase in colon cancer cells. *Oncology Reports*. <https://doi.org/10.3892/or.2012.1644>
- Klos, P., & Chlubek, D. (2022). Plant-Derived Terpenoids: A Promising Tool in the Fight against Melanoma. *Cancers*, 14(3), 502. <https://doi.org/10.3390/cancers14030502>
- Kossatz, S., Brand, C., Gutiontov, S., Liu, J. T. C., Lee, N. Y., Gönen, M., Weber, W. A., & Reiner, T. (2016). Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. *Scientific Reports*, 6(1), 21371. <https://doi.org/10.1038/srep21371>
- Kumar, M., & Jha, A. K. (2023). Exploring the potential of dietary factors and plant extracts as chemopreventive agents in oral squamous cell carcinoma treatment. *Frontiers in Oral Health*, 4, 1246873. <https://doi.org/10.3389/froh.2023.1246873>
- Kwon, H. J., Hong, Y. K., Park, C., Choi, Y. H., Yun, H. J., Lee, E. W., & Kim, B. W. (2010). Widdrol induces cell cycle arrest, associated with MCM down-regulation, in human colon adenocarcinoma cells. *Cancer Letters*, 290(1), 96–103. <https://doi.org/10.1016/j.canlet.2009.09.003>
- Lee, S., Rauch, J., & Kolch, W. (2020). Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. *International Journal of Molecular Sciences*, 21(3), 1102. <https://doi.org/10.3390/ijms21031102>
- Li, L., Mangali, S., Kour, N., Dasari, D., Ghatage, T., Sharma, V., Dhar, A., & Bhat, A. (2021). *Syzygium cumini* (jamun) fruit-extracted phytochemicals exert anti-proliferative effect on ovarian cancer cells. *Journal of Cancer Research and Therapeutics*, 17(6), 1547–1551. [https://doi.org/10.4103/jcrt.jcrt\\_210\\_20](https://doi.org/10.4103/jcrt.jcrt_210_20)
- Li, M., Zhan, J., Lai, Y., Ma, Y., Wei, H., Jiang, L., Zha, J., Shao, Y., & Wang, W. (2025). The mechanisms of *Brucea javanica* in the treatment of oral squamous cell carcinoma: A network pharmacology, molecular docking, and experimental study. *European Journal of Medical Research*, 30(1), 439. <https://doi.org/10.1186/s40001-025-02686-1>
- Li, Y.-C., Cheng, A.-J., Lee, L.-Y., Huang, Y.-C., & Chang, J. T.-C. (2019). Multifaceted Mechanisms of Areca Nuts in Oral Carcinogenesis: The Molecular Pathology from Precancerous Condition to Malignant Transformation. *Journal of Cancer*, 10(17), 4054–4062. <https://doi.org/10.7150/jca.29765>
- Li, Z., Liu, F., & Kirkwood, K. L. (2020). The p38/MKP-1 signaling axis in oral cancer: Impact of tumor-associated macrophages. *Oral Oncology*, 103, 104591. <https://doi.org/10.1016/j.oraloncology.2020.104591>
- Lichota, A., & Gwozdziński, K. (2018). Anticancer Activity of Natural Compounds from Plant and Marine Environment. *International Journal of Molecular Sciences*, 19(11), 3533. <https://doi.org/10.3390/ijms19113533>
- Lu, L., Xue, X., Lan, J., Gao, Y., Xiong, Z., Zhang, H., Jiang, W., Song, W., & Zhi, Q. (2014). MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. *Biomedicine & Pharmacotherapy*, 68(1), 13–19. <https://doi.org/10.1016/j.biopha.2013.10.005>
- Mashhadiabbas, F., Mahjour, F., Mahjour, S. B., Fereidooni, F., & Hosseini, F. S. (2012). The immunohistochemical characterization of MMP-2, MMP-10, TIMP-1, TIMP-2, and podoplanin in oral squamous cell carcinoma. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, 114(2), 240–250. <https://doi.org/10.1016/j.oooo.2012.04.009>
- Menditti, D., Santagata, M., Imola, G., Stagliano, S., Vitagliano, R., Boschetti, C. E., & Inchingolo, A. M. (2023). Personalized Medicine in Oral Oncology: Imaging Methods and Biological Markers to Support Diagnosis of Oral Squamous Cell Carcinoma (OSCC): A Narrative Literature Review. *Journal of Personalized Medicine*, 13(9), 1397. <https://doi.org/10.3390/jpm13091397>
- Miguelanez-Medran, B., Pozo-Kreilinger, J., Cebrian-Carretero, J., Martinez-Garcia, M., & Lopez-Sanchez, A. (2019). Oral squamous cell carcinoma of tongue: Histological risk assessment. A pilot study. *Medicina Oral Patología Oral y Cirugía Bucal*, 0–0. <https://doi.org/10.4317/medoral.23011>
- Mitea, G., Schröder, V., & Iancu, I. M. (2025). Bioactive Plant-Derived Compounds as Novel Perspectives in Oral Cancer Alternative Therapy. *Pharmaceuticals*, 18(8), 1098. <https://doi.org/10.3390/ph18081098>
- Mohanraj, K., Karthikeyan, B. S., Vivek-Ananth, R. P., Chand, R. P. B., Aparna, S. R., Mangalapandi, P., & Samal, A. (2018). IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry And Therapeutics. *Scientific Reports*, 8(1), 4329. <https://doi.org/10.1038/s41598-018-22631-z>
- Mohtasham, N., Babakoohi, S., Shiva, A., Shadman, A., Kamyab-Hesari, K., Shakeri, M.-T., & Sharifi-Sistani, N. (2013). Immunohistochemical study of p53, Ki-67, MMP-2 and MMP-9 expression at invasive front of squamous cell and verrucous carcinoma in oral cavity. *Pathology - Research and Practice*, 209(2), 110–114. <https://doi.org/10.1016/j.prp.2012.11.002>
- Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *Journal of Computational Chemistry*, 30(16), 2785–2791. <https://doi.org/10.1002/jcc.21256>
- Parrinello, M., & Rahman, A. (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. *Journal of Applied Physics*, 52(12), 7182–7190. <https://doi.org/10.1063/1.328693>
- Patel, B. P., Shah, P. M., Rawal, U. M., Desai, A. A., Shah, S. V., Rawal, R. M., & Patel, P. S. (2005). Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. *Journal*

- of Surgical Oncology, 90(2), 81–88. <https://doi.org/10.1002/jso.20240>
- Patil, R., Mahajan, A., Pradeep, G. L., Prakash, N., Patil, S., & Khan, S. M. (2021). Expression of matrix metalloproteinase-9 in histological grades of oral squamous cell carcinoma: An immunohistochemical study. *Journal of Oral and Maxillofacial Pathology*, 25(2), 239–246. <https://doi.org/10.4103/0973-029X.325121>
- Peng, Q., Deng, Z., Pan, H., Gu, L., Liu, O., & Tang, Z. (2017). Mitogen-activated protein kinase signaling pathway in oral cancer (Review). *Oncology Letters*. <https://doi.org/10.3892/ol.2017.7491>
- Pramanik, K. K., & Mishra, R. (2022). ERK-mediated upregulation of matrix metalloproteinase-2 promotes the invasiveness in human oral squamous cell carcinoma (OSCC). *Experimental Cell Research*, 411(1), 112984. <https://doi.org/10.1016/j.yexcr.2021.112984>
- Qamar, M., Akhtar, S., Ismail, T., Wahid, M., Abbas, M. W., Mubarak, M. S., Yuan, Y., Barnard, R. T., Ziora, Z. M., & Esatbeyoglu, T. (2022). Phytochemical Profile, Biological Properties, and Food Applications of the Medicinal Plant *Syzygium cumini*. *Foods*, 11(3), 378. <https://doi.org/10.3390/foods11030378>
- Ramsridhar, S., Rajkumar, C., Veeraraghavan, V. P., Francis, A. P., Balasubramaniam, M., & Bharkavi, I. (2025). From cell lines to animal models: “Plant-derived chemotherapeutics unlocking new frontiers against oral squamous cell carcinoma”—a comprehensive systematic review. *Discover Oncology*, 16(1). <https://doi.org/10.1007/s12672-025-02057-6>
- Ravi Ahirwar\*, S. K. (2025). Phytochemical Screening of Jamun Seed (*Syzygium Cumini*). <https://doi.org/10.5281/ZENODO.15529877>
- Rodriguez, S., Sueiro, R. A., Murray, A. P., & Leiro, J. M. (2019). Bioactive Sesquiterpene Obtained from *Schinus areira* L. (Anacardiaceae) Essential Oil. The 23rd International Electronic Conference on Synthetic Organic Chemistry, 85. <https://doi.org/10.3390/ecsoc-23-06649>
- Sakuludomkan, C., Khowsathit, J., Thippraphan, P., Koonrunsesomboon, N., Takuathung, M. N., & Taychaworaditsakul, W. (2025). Network Pharmacology and Molecular Docking-Based Approach to Explore Potential Bioactive Compounds from *Kaempferia parviflora* on Chemokine Signaling Pathways in the Treatment of Psoriasis Disease. *International Journal of Molecular Sciences*, 26(11), 5243. <https://doi.org/10.3390/ijms26115243>
- Salehi, B., Upadhyay, S., Erdogan Orhan, I., Kumar Jugran, A., L.D. Jayaweera, S., A. Dias, D., Sharopov, F., Taheri, Y., Martins, N., Baghalpour, N., C. Cho, W., & Sharifi-Rad, J. (2019). Therapeutic Potential of  $\alpha$ - and  $\beta$ -Pinene: A Miracle Gift of Nature. *Biomolecules*, 9(11), 738. <https://doi.org/10.3390/biom9110738>
- Sanyal, S., Amin, Sk. A., Banerjee, P., Gayen, S., & Jha, T. (2022). A review of MMP-2 structures and binding mode analysis of its inhibitors to strategize structure-based drug design. *Bioorganic & Medicinal Chemistry*, 74, 117044. <https://doi.org/10.1016/j.bmc.2022.117044>
- Sawant, L., Singh, V. K., Dethé, S., Bhaskar, A., Balachandran, J., Mundkinajeddu, D., & Agarwal, A. (2015). Aldose reductase and protein tyrosine phosphatase 1B inhibitory active compounds from *Syzygium cumini* seeds. *Pharmaceutical Biology*, 53(8), 1176–1182. <https://doi.org/10.3109/13880209.2014.967784>
- Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. *Genome Research*, 13(11), 2498–2504. <https://doi.org/10.1101/gr.1239303>
- Sharmila, A., Bhadra, P., Kishore, C., Selvaraj, C. I., Kavalakatt, J., & Bishayee, A. (2025). Nanoformulated Terpenoids in Cancer: A Review of Therapeutic Applications, Mechanisms, and Challenges. *Cancers*, 17(18), 3013. <https://doi.org/10.3390/cancers17183013>
- Shrestha, B., Bajracharya, D., Byatnal, A. A., Kamath, A., & Radhakrishnan, R. (2017). May High MMP-2 and TIMP-2 Expressions Increase or Decrease the Aggressivity of Oral Cancer? *Pathology & Oncology Research*, 23(1), 197–206. <https://doi.org/10.1007/s12253-016-0149-3>
- Singh, J., Jain, T., Agrawal, R., & Chandra, A. (2022). Inflammation and oral cancer. *International Journal of Oral Health Sciences*, 12(2), 46–49. [https://doi.org/10.4103/ijohs.ijohs\\_8\\_22](https://doi.org/10.4103/ijohs.ijohs_8_22)
- Stelzer, G., Rosen, N., Plaschkes, I., Zimmerman, S., Twik, M., Fishilevich, S., Stein, T. I., Nudel, R., Lieder, I., Mazor, Y., Kaplan, S., Dahary, D., Warshawsky, D., Guan-Golan, Y., Kohn, A., Rappaport, N., Safran, M., & Lancet, D. (2016). The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. *Current Protocols in Bioinformatics*, 54, 1.30.1-1.30.33. <https://doi.org/10.1002/cpbi.5>
- Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A. L., Fang, T., Doncheva, N. T., Pyysalo, S., Bork, P., Jensen, L. J., & von Mering, C. (2023). The STRING database in 2023: Protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Research*, 51(D1), D638–D646. <https://doi.org/10.1093/nar/gkac1000>
- Tamamura, R., Nagatsuka, H., Siar, C. H., Katase, N., Naito, I., Sado, Y., & Nagai, N. (2013). Comparative analysis of basal lamina type IV collagen  $\alpha$  chains, matrix metalloproteinases-2 and -9 expressions in oral dysplasia and invasive carcinoma. *Acta Histochemica*, 115(2), 113–119. <https://doi.org/10.1016/j.acthis.2012.05.001>
- Tan, Y., Wang, Z., Xu, M., Li, B., Huang, Z., Qin, S., Nice, E. C., Tang, J., & Huang, C. (2023). Oral squamous cell carcinomas: State of the field and emerging directions. *International Journal of Oral Science*, 15(1). <https://doi.org/10.1038/s41368-023-00249-w>
- Tavares, I. M. D. C., Lago-Vanzela, E. S., Rebello, L. P. G., Ramos, A. M., Gómez-Alonso, S., García-Romero, E., Da-Silva, R., & Hermosín-Gutiérrez, I. (2016). Comprehensive study of the phenolic composition of the edible parts of jambolan fruit (*Syzygium cumini* (L.) Skeels). *Food Research International*, 82, 1–13. <https://doi.org/10.1016/j.foodres.2016.01.014>
- Tenore, G., Nuvoli, A., Mohsen, A., Cassoni, A., Battisti, A., Terenzi, V., Della Monaca, M., Raponi, I., Brauner, E., De Felice, F., Musio, D., Di Gioia, C. R. T., Messineo, D., Mezi, S., Di Carlo, S., Botticelli, A., Valentini, V., Marchetti, P., Tombolini, V., ... Romeo, U. (2020). Tobacco, Alcohol and Family History of Cancer as Risk Factors of Oral Squamous Cell Carcinoma: Case-Control Retrospective Study. *Applied Sciences*, 10(11), 3896. <https://doi.org/10.3390/app10113896>
- Vilen, S.-T., Salo, T., Sorsa, T., & Nyberg, P. (2013). Fluctuating Roles of Matrix Metalloproteinase-9 in Oral Squamous Cell Carcinoma. *The Scientific World Journal*, 2013(1), 920595. <https://doi.org/10.1155/2013/920595>
- Wang, F., Gouttia, O. G., Wang, L., & Peng, A. (2022). PARP1 Upregulation in Recurrent Oral Cancer and Treatment Resistance.

- Frontiers in Cell and Developmental Biology, 9, 804962. <https://doi.org/10.3389/fcell.2021.804962>
- Wasim, M., & Bergonzi, M. C. (2024). Unlocking the Potential of Oleanolic Acid: Integrating Pharmacological Insights and Advancements in Delivery Systems. *Pharmaceutics*, 16(6), 692. <https://doi.org/10.3390/pharmaceutics16060692>
- Widiyarti, G., Megawati, M., & Hanafi, M. (2019). The Potential use of Geraniol Esters from Citronella Oil as Anticancer Agents. *Oriental Journal of Chemistry*, 35(3), 987–996. <https://doi.org/10.13005/ojc/350310>
- Yang, J.-B., Li, M., Xie, J.-J., Yang, M.-D., Lu, X.-S., Wang, F., & Chen, W.-Q. (2016). [Effects of  $\alpha$ -pinene extracted from pine needle on expression of miR-221 and its potential target genes in human hepatocellular carcinoma cells]. *Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica*, 41(21), 3996–3999. <https://doi.org/10.4268/cjcm20162118>
- Yang, S., Zhao, M., Lu, M., Feng, Y., Zhang, X., Wang, D., & Jiang, W. (2024). Network Pharmacology Analysis, Molecular Docking Integrated Experimental Verification Reveal the Mechanism of *Gynostemma pentaphyllum* in the Treatment of Type II Diabetes by Regulating the IRS1/PI3K/Akt Signaling Pathway. *Current Issues in Molecular Biology*, 46(6), 5561–5581. <https://doi.org/10.3390/cimb46060333>
- Yang, W.-E., Ho, Y.-C., Tang, C.-M., Hsieh, Y.-S., Chen, P.-N., Lai, C.-T., Yang, S.-F., & Lin, C.-W. (2019). *Duchesnea indica* extract attenuates oral cancer cells metastatic potential through the inhibition of the matrix metalloproteinase-2 activity by down-regulating the MEK/ERK pathway. *Phytomedicine*, 63, 152960. <https://doi.org/10.1016/j.phymed.2019.152960>
- Ye, H., Yu, T., Temam, S., Ziober, B. L., Wang, J., Schwartz, J. L., Mao, L., Wong, D. T., & Zhou, X. (2008). Transcriptomic dissection of tongue squamous cell carcinoma. *BMC Genomics*, 9(1), 69. <https://doi.org/10.1186/1471-2164-9-69>
- Yu, Z., Wu, Y., Ma, Y., Cheng, Y., Song, G., & Zhang, F. (2022). Systematic analysis of the mechanism of aged citrus peel (Chenpi) in oral squamous cell carcinoma treatment via network pharmacology, molecular docking and experimental validation. *Journal of Functional Foods*, 91, 105012. <https://doi.org/10.1016/j.jff.2022.105012>
- Zhai, Z., Tao, X., Alami, M. M., Shu, S., & Wang, X. (2021). Network Pharmacology and Molecular Docking Combined to Analyze the Molecular and Pharmacological Mechanism of *Pinellia ternata* in the Treatment of Hypertension. *Current Issues in Molecular Biology*, 43(1), 65–78. <https://doi.org/10.3390/cimb43010006>
- Zhao, S., Xiao, S., Wang, W., Dong, X., Liu, X., Wang, Q., Jiang, Y., & Wu, W. (2024). Network pharmacology and transcriptomics reveal the mechanisms of FFBZL in the treatment of oral squamous cell carcinoma. *Frontiers in Pharmacology*, 15. <https://doi.org/10.3389/fphar.2024.1405596>
- Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., & Chanda, S. K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nature Communications*, 10(1). <https://doi.org/10.1038/s41467-019-09234-6>
- Zoete, V., Cuendet, M. A., Grosdidier, A., & Michielin, O. (2011). SwissParam: A fast force field generation tool for small organic molecules. *Journal of Computational Chemistry*, 32(11), 2359–2368. <https://doi.org/10.1002/jcc.21816>

## SUPPLEMENTARY

Table S1

Active phytochemical compounds of *Syzygium cumini*.

S.No	Indian medicinal plant	Plant part	Phytochemical name
1.	<i>Syzygium cumini</i>	fruit	Malvidin 3-laminaribioside
2.	<i>Syzygium cumini</i>	fruit	Delphinidin 3-gentiobioside
3.	<i>Syzygium cumini</i>	fruit	Petunidin 3-gentiobioside
4.	<i>Syzygium cumini</i>	fruit	Flavylum
5.	<i>Syzygium cumini</i>	fruit	Myrcene
6.	<i>Syzygium cumini</i>	fruit	Citric acid
7.	<i>Syzygium cumini</i>	fruit	Dihydrocarvyl acetate
8.	<i>Syzygium cumini</i>	fruit	Geranyl butyrate
9.	<i>Syzygium cumini</i>	fruit	Palmitic acid
10.	<i>Syzygium cumini</i>	fruit	Widdrol
11.	<i>Syzygium cumini</i>	fruit	Oxalic acid
12.	<i>Syzygium cumini</i>	fruit	gamma-Decalactone
13.	<i>Syzygium cumini</i>	fruit	4-Carvomenthenol
14.	<i>Syzygium cumini</i>	fruit	Terpinolene
15.	<i>Syzygium cumini</i>	fruit	cis-beta-Farnesene
16.	<i>Syzygium cumini</i>	fruit	Humulene
17.	<i>Syzygium cumini</i>	fruit	Oleanolic acid
18.	<i>Syzygium cumini</i>	fruit	Gallic acid
19.	<i>Syzygium cumini</i>	fruit	Linalool
20.	<i>Syzygium cumini</i>	fruit	alpha-Pinene
21.	<i>Syzygium cumini</i>	fruit	beta-Pinene
22.	<i>Syzygium cumini</i>	fruit	alpha-Terpineol
23.	<i>Syzygium cumini</i>	fruit	delta-Cadinol
24.	<i>Syzygium cumini</i>	fruit	(Z)-beta-Ocimene
25.	<i>Syzygium cumini</i>	fruit	(-)-Globulol
26.	<i>Syzygium cumini</i>	fruit	beta-Caryophyllene
27.	<i>Syzygium cumini</i>	fruit	(E)-beta-ocimene
28.	<i>Syzygium cumini</i>	fruit	Bornyl acetate
29.	<i>Syzygium cumini</i>	fruit	cis-Nerolidol
30.	<i>Syzygium cumini</i>	fruit	6-Epi-beta-bisabolol
31.	<i>Syzygium cumini</i>	fruit	Ledol
32.	<i>Syzygium cumini</i>	fruit	cis-Dihydrocarvone

**Table S2**Pharmacokinetic properties of the 32 phytochemical constituents identified in *Syzygium cumini*.

Phytochemical compounds	Molecular weight (g/mol)	H-bond acceptors	H-bond donors	XLOGP3	Lipinski violations	Bioavailability Score
Malvidin 3-laminaribioside	655.58	17	10	-1.16	3	0.17
Delphinidin 3-gentiobioside	627.52	17	12	-2.36	3	0.17
Petunidin 3-gentiobioside	641.55	17	11	-2.04	3	0.17
Flavylum	207.25	1	0	3.51	0	0.55
Myrcene	136.23	0	0	4.17	0	0.55
Citric acid	192.12	7	4	-1.72	0	0.56
Dihydrocarvyl acetate	196.29	2	0	3.78	0	0.55
Geranyl butyrate	224.34	2	0	4.87	0	0.55
Palmitic acid	256.42	2	1	7.17	1	0.85
Widdrol	222.37	1	1	4.08	0	0.55
Oxalic acid	90.03	4	2	-0.25	0	0.85
gamma-Decalactone	170.25	2	0	2.72	0	0.55
4-Carvomenthenol	154.25	1	1	3.26	0	0.55
Terpinolene	136.23	0	0	4.47	0	0.55
cis-beta-Farnesene	204.35	0	0	6.03	1	0.55
Humulene	204.35	0	0	4.55	1	0.55
Oleanolic acid	456.7	3	2	7.49	1	0.85
Gallic acid	170.12	5	4	0.7	0	0.56
Linalool	154.25	1	1	2.97	0	0.55
alpha-Pinene	136.23	0	0	4.48	1	0.55
beta-Pinene	136.23	0	0	4.16	1	0.55
alpha-Terpineol	154.25	1	1	3.39	0	0.55
delta-Cadinol	222.37	1	1	3.34	0	0.55
(Z)-beta-Ocimene	136.23	0	0	4.26	0	0.55
(-)-Globulol	222.37	1	1	3.74	0	0.55
beta-Caryophyllene	204.35	0	0	4.38	1	0.55
(E)-beta-ocimene	136.23	0	0	4.26	0	0.55
Bornyl acetate	196.29	2	0	4.3	0	0.55
cis-Nerolidol	222.37	1	1	4.83	0	0.55
6-Epi-beta-bisabolol	222.37	1	1	5.04	0	0.55
Ledol	222.37	1	1	3.74	0	0.55
cis-Dihydrocarvone	152.23	1	0	2.85	0	0.55




Figure S1




Figure S2